Dr. Gaudet founded the Université de Montréal Community Genomics Medicine Center, the Lipid Research Group and the Lipid Clinic at the Chicoutimi Hospital, where he was also director of research from 2003 to 2012.

In 2000, Dr. Gaudet founded ECOGENE-21, a non-profit organization in translational medicine and systems approach whose aim is the acquisition of new knowledge, the development and evaluation of diagnostic tools, novel treatments and technologies from research in genetics and omic sciences, and their application to clinical practice at the community level. The ECOGENE-21 Clinical Research Center operates in conjunction with Boréal Pharma Recherche Clinique and employs a workforce of some 25 qualified research assistants and professionals, all trained in Good Clinical Practices (GCP). It gathers well-equipped laboratories, and executes some 15 to 20 clinical studies each year.  Its offer of services extends to acting as central laboratory and coordination center for complexes studies, from proof of concept (PoC) to early development phases. Under the direction of Dr Gaudet, ECOGENE-21 successfully developed and transferred to clinical and public health services a low-cost multiplex test now used to carry out a Quebec Heath Ministry pilot project offering simultaneous carrier testing for four recessive diseases. Dr Gaudet receives the Biotechnology of Tomorrow Award at the 2012 Genesis Award Gala for these works.

Over the years, he has coordinated more than 120 clinical studies (PoC and phase I to IIIb) and academic projects involving the development of new drugs, technologies and innovative treatments (gene and antisens therapies), especially in genetic lipid disorders, metabolic syndrome and associated risks, among which the first gene therapy having received a regulatory approval for a commercial treatment. He is the author, or co-author, of several hundred scientific communications, more than 170 publications in peer-reviewed journals, 8 technological patents as well as published works for clinicians.

Dr Gaudet has also served on numerous national and international scientific valuation committees, including the European Union’s Seventh Framework Programme (FP7) for Research and Technological Development. He member of the Board of Directors of the Fonds de la recherche en santé du Québec (FRQS) and member of the FRSQ finance committee and founding the Société québécoise de lipidologie, nutrition et métabolism inc. From 1998 to 1001, he was Chairman of the Board of the Corporation for Research and Action on Hereditary Diseases (CORAMH). As consulting physician in genetics with the Public Health Bureau of the Saguenay–Lac-Saint-Jean region since 1994, he coordinated the creation of the region’s community genetics service plan and was actively involved in the World Health Organization (WHO) community genetics program (1998-2003) as well as in the WHO report on familial hypercholesterolemia.


Panel Discussion: Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemia91th EAS Congress 2023Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemiaHomozygous familial hypercholesterolaemia: disease overview, goals of treatment and unmet need91th EAS Congress 2023Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemiaEAS Advanced Course – Rare Lipid Disorders - France & SwitzerlandWebinars on-demandEmerging therapies for dyslipidemia90th EAS Congress 2022Plenary 2: Lipoproteins revisited: What has changed ?A first-in-human single ascending dose study of a monoclonal antibody against the ANGPTL3/8 complex in subjects with mixed hyperlipidemia90th EAS Congress 2022Late breaker session 1HOFH: new insights in therapeutic approaches - Discussion and Q&AFH Week90th EAS Congress 2022HOFH: new insights in therapeutic approaches(LipidologyMetab lipoLDL)Novel therapeutic options90th EAS Congress 2022HOFH: new insights in therapeutic approaches